Review Darunavir: pharmacokinetics and drug interactions

Darunavir (TMC114) is a new HIV protease inhibitor that has demonstrated substantial antiretroviral activity against wild-type HIV-1 virus and multidrug-resistant strains. Darunavir inhibits and is primarily metabolized by cytochrome P450 3A (CYP3A) isoenzymes and is coadministered with low-dose ritonavir (darunavir/r); ritonavir is an inhibitor of CYP3A isoenzymes and pharmacologically enhances darunavir, resulting in increased plasma concentrations and allowing for a lower daily dose. The t1/2 (terminal elimination half-life) of darunavir is 15 h in the presence of ritonavir. An extensive darunavir/r drug‐drug interaction programme has been undertaken, covering a wide range of therapeutic areas. Studies conducted in HIV-negative healthy volunteers and in HIV-infected patients show that the potential for interactions is well characterized and the interactions are manageable. For most drugs investigated, no dose adjustments of darunavir/r or the co-administered drug are required. This article reviews all the pharmacokinetic and drug‐drug interaction studies conducted to date for darunavir/r, providing guidance on how to co-administer darunavir/r with many other antiretroviral or non-antiretroviral medications commonly used in HIV-infected individuals.

[1]  A. Hill,et al.  Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. , 2007, British journal of clinical pharmacology.

[2]  C. Katlama,et al.  Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in Treatment-Experienced Patients: 24-Week Results of POWER 3 , 2007, Journal of acquired immune deficiency syndromes.

[3]  M. Peeters,et al.  Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers , 2007, Antiviral therapy.

[4]  M. Peeters,et al.  Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers , 2007, Antiviral therapy.

[5]  R. Haubrich,et al.  Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials , 2007, The Lancet.

[6]  R. Hoetelmans,et al.  The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV‐Negative Healthy Volunteers , 2007, Journal of clinical pharmacology.

[7]  R. Haubrich,et al.  Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients , 2007, AIDS.

[8]  L. Waters,et al.  8th International Congress on Drug Therapy in HIV Infection , 2007 .

[9]  C. Katlama,et al.  Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 , 2007, AIDS.

[10]  R. Bonomo,et al.  46th Interscience Conference on Antimicrobial Agents and Chemotherapy. , 2007, Future microbiology.

[11]  R. Hoetelmans,et al.  Pharmacokinetic Interaction between Darunavir Boosted with Ritonavir and Omeprazole or Ranitidine in Human Immunodeficiency Virus-Negative Healthy Volunteers , 2007, Antimicrobial Agents and Chemotherapy.

[12]  R. Ebrahimi,et al.  Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/Ritonavir , 2006, Journal of acquired immune deficiency syndromes.

[13]  V. Sekar.  Pharmacokinetic Interaction Between the HIV Protease Inhibitors TMC114 and Saquinavir, in the Presence of Low-Dose Ritonavir , 2006 .

[14]  V. Sekar.  Pharmacokinetic Interaction Between the Antiretroviral Agents TMC114 and Nevirapine, in the Presence of Low-Dose Ritonavir , 2006 .

[15]  V. Sekar.  Pharmacokinetic Interaction Between TMC114 and Ketoconazole, in the Absence and Presence of Low-Dose Ritonavir , 2006 .

[16]  D. Back.  Drug-drug interactions that matter. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[17]  V. Calvez,et al.  Salvage Therapy with Atazanavir/Ritonavir Combined to Tenofovir in HIV-Infected Patients with Multiple Treatment Failures: Randomized Anrs 107 Trial , 2006, Antiviral therapy.

[18]  M. Boffito,et al.  Practical Perspectives on the Use of Tipranavir in Combination With Other Medications: Lessons Learned From Pharmacokinetic Studies , 2006, Journal of clinical pharmacology.

[19]  R. Hoetelmans,et al.  PI‐61 , 2006 .

[20]  J. Montaner,et al.  Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks , 2005, Journal of acquired immune deficiency syndromes.

[21]  Dorothea C. Rudorf,et al.  Drug-Drug Interactions and HIV Therapy: What Should Pharmacists Know? , 2005 .

[22]  A. Winston,et al.  The management of HIV-1 protease inhibitor pharmacokinetic interactions. , 2005, The Journal of antimicrobial chemotherapy.

[23]  Dirk Jochmans,et al.  TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[24]  M. Kurowski,et al.  Current Status and Future Prospects of Therapeutic Drug Monitoring and Applied Clinical Pharmacology in Antiretroviral Therapy , 2005, Antiviral therapy.

[25]  Celia A Schiffer,et al.  Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. , 2005, Journal of medicinal chemistry.

[26]  J. Wangsa,et al.  Effect of Multiple‐Dose Dexloxiglumide on the Pharmacokinetics of Oral Contraceptives in Healthy Women , 2005, Journal of clinical pharmacology.

[27]  M. Kurowski,et al.  The Steady-State Pharmacokinetics of Nelfinavir in Combination with Tenofovir in HIV-Infected Patients , 2005, Antiviral therapy.

[28]  Celia A. Schiffer,et al.  Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor , 2004, Journal of Virology.

[29]  S. Walmsley,et al.  Polypharmacy in HIV: impact of data source and gender on reported drug utilization. , 2004, AIDS patient care and STDs.

[30]  P. Anderson,et al.  6th International Workshop on Clinical Pharmacology of HIV Therapy , 2004, Expert opinion on pharmacotherapy.

[31]  Irene T Weber,et al.  High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. , 2004, Journal of molecular biology.

[32]  M. Boffito,et al.  Pharmacokinetic considerations for combining 2 protease inhibitors. , 2004, The AIDS reader.

[33]  Irene T. Weber,et al.  Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.

[34]  E. Freire,et al.  The binding of HIV-1 protease inhibitors to human serum proteins. , 2003, Biophysical chemistry.

[35]  P. Jatlow,et al.  The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  T. Antoniou,et al.  Interactions between Recreational Drugs and Antiretroviral Agents , 2002, The Annals of pharmacotherapy.

[37]  A. Molla,et al.  In Vitro Antiviral Interaction of Lopinavir with Other Protease Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.

[38]  J. Polli,et al.  Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[39]  L. Highleyman.  Protease inhibitors and sildenafil (Viagra) should not be combined. , 1999, BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation.

[40]  J. Kuper,et al.  Drug Interactions of HIV Protease Inhibitors , 1999, Drug safety.

[41]  A. T. Harvey,et al.  Biochemical and clinical dose‐response curves with sertraline , 1996 .

[42]  C. Bye,et al.  Paroxetine plasma levels: lack of correlation with efficacy or adverse events , 1989, Acta psychiatrica Scandinavica. Supplementum.

[43]  R. Hoetelmans,et al.  Pharmacokinetics of Darunavir (TMC114) and Atazanavir during Coadministration in HIV-Negative, Healthy Volunteers , 2007, Drugs in R&D.

[44]  Henry J. Kaiser,et al.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. , 1998, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.